PTGS2

Across TCGA pan-cancer cohorts, PTGS2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PTGS2 data layer compared with 28 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PTGS2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTGS2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, LIHC, and UCEC are the cancer types where PTGS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.188	0.820	<.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCEC	DFS	Median	All	0.937	0.617	.020	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PTGS2–ACC (OS)

Open the ACC breakdown →